Introduction:　The　effectiveness　of　programmed　cell　death　protein　1　(PD-1)　and　programmed　cell　death　ligand　1　(PD-L1)　on　tumor　has　been　reported.　However,　the　immune-related　adverse　events　(irAEs)　and　its　clinical　management　of　the　immune　checkpoint　inhibitors　(ICIs)　have　not　been　fully　understood.　We　aimed　to　analyze　the　irAEs　and　its　ICIs　targeting　the　PD-1/PD-L1.　Methods:　The　retrospective　analysis　was　performed　on　the　irAEs　of　cancer　patients　treated　with　anti-PD1/PD-L1　monoclonal　antibodies　from　January　2020　to　August　2021　including　240　patients/547　cycles.　The　following　aspects　including　the　categories　and　the　grades　of　the　adverse　events　(AEs),　the　time　of　onset　and　duration,　management　plan,　and　prognosis　were　evaluated.　Results:　Among　240　patients,　93　patients　(38.75%)　experienced　irAEs,　and　10　patients　(4.16%)　had　AEs　that　involved　multiple　organ　systems　at　the　same　time.　There　were　83　cases　(34.58%)　of　grade　1-2　AEs　and　10　cases　(4.17%)　of　grade　three　and　above　AEs.　AEs　above　grade　three　included　five　cases　of　grade　three　AEs　(3　cases　of　hepatic　toxicity,　one　case　of　colitis,　and　one　case　of　skin　toxicity),　three　cases　of　grade　four　AEs　(pneumonia);　and　2　cases　of　grade　five　AEs　(two　deaths　due　to　pneumonia).　The　complete　remission　of　AEs　was　achieved　in　10　patients　by　corticosteroid　impulse　therapy,　maintenance　therapy,　and　symptomatic　therapy.　Among　them,　six　cases　continued　to　use　anti-PD1/PD-L1　monoclonal　antibodies,　two　cases　stopped,　and　two　patients　died　from　systemic　multi-organ　failure　due　to　the　delayed　observation　of　autoimmune　pneumonia.　IrAEs　occurred　at　different　times　and　durations　in　different　systems　or　organs.　Conclusion:　The　safety　of　PD-1/PD-L1　inhibitors　was　approved　in　clinical　applications.　The　prevalence　of　grade　three　and　above　AEs　is　relatively　low.　Timely　diagnosis　and　early　glucocorticoid　therapies　are　adequate　and　effective　approaches　for　the　management　of　irAEs.